We’ve worked hard to support Treatment for All by expanding opportunities for connection and hemophilia care by partnering with those at the forefront of change.
Genentech created the first cloned, virus-free, nonblood-derived factor VIII protein using recombinant DNA (RDNA) technology*
*Genentech outlicensed worldwide production and marketing of factor VIII.
Genentech begins its partnership with Chugai Pharmaceutical
Working with Chugai, research begins on innovative approaches to treatment of hemophilia A
Genentech’s parent company, Roche, joins the European Haemophilia Consortium PARTNERS program to provide better treatment access to people with hemophilia A around the world
Genentech and our parent company Roche joins the World Federation of Hemophilia Humanitarian Aid Program to provide treatment to people with hemophilia A in developing countries
Genentech partners with the University of Pennsylvania Positive Psychology Center to explore how the science of positive psychology can help people with hemophilia thrive in times of change through interactive workshops
Genentech launches its new series, CHALLENGE ACCEPTED, which dives into the real, everyday challenges of living with hemophilia
Genentech and our parent company Roche supports Save One Life’s Micro-Enterprise Grant program to help people with bleeding disorders in developing countries establish or grow their small businesses
The link you have selected will take you to the Challenge Accepted YouTube page to watch Season 1. YouTube is not owned or controlled by Genentech, Inc. Your use of YouTube.com is at your own risk and subject to the terms and conditions of use for that site.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.